Scientific consensus is evolving, but PrEP clinical equity remains unachieved. Recent data has challenged the “conventional wisdom” surrounding vaginal PrEP tissue concentrations, proving oral PrEP (TDF/FTC, TAF/FTC) is significantly more forgiving than historic messaging for ciswomen suggested. This has implications for what we understand as “time to protection” as well as “on-demand” PrEP, and may impact trans and non-binary people as well.
What will it take to update the discordant guidelines for women? Can better, more accurate alignment advance equity for ciswomen, transfolks and non-binary people?
Speakers:
- Heather-Marie Anne Schmidt, UNAIDS
- Simon Collins, HIV i-Base
- Dr. Jenell Stewart, University of Minnesota
- Dr. Raphael Landovitz, University of California Los Angeles
